Clinical Trial Search

Primary: The Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes Through Week 48 of the Study in the Intent-to-treat Population. — 2; 3; 0; 2 Participants

Primary: Hospital Mortality — 95 Participants

Primary: Percentage of Subjects With Therapeutic Cure at 28 Days for All-Analysis Population — 9; 9; 11; 10 Participants

Primary: Stool Fungal Burden — 500; 55000; 1671; 622.5 cfu per gram — p=0.9

Primary: Percentage of Participants With Global Treatment Response Success at End of Treatment — 69.5 percentage of participants

Primary: Number of Participants With Clinical Resolution of Injected Wart — 9; 1; 1 Participants

Primary: Proven and Probable Invasive Candidiasis Based on Modified Mycoses Study Group/European Organization for Research and Treatment of Cancer (MSG/EORTC) Criteria. — 9.8…

Primary: Number of Participants With Complete Resolution of Primary Injected Wart — 19 Participants

Primary: Percentage of Participants With Overall Response of Success at the End of Intravenous Therapy (EOIV) as Determined by the Data Review Committee (DRC) Based on the…

Primary: Number of Patients Who Develop Significant Drug-related Adverse Events. — 2; 3 Participants

Primary: Percentage of Subjects With 1 or More Culture-Verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-Treat Population — 6.7; 42.8…

Primary: Clinical Response to Treatment of Mucocutaneous Candidiasis — 4 Participants

Primary: Number of Subjects With Global Response of Success at End of Treatment — 31 participants

Primary: Therapeutic Outcome: Response Rate — 33.7; 54.2; 74.7 percentage of participants

Primary: Mean Time to Itch Relief — 13.36 minutes

Primary: Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-treat (ITT) Population. — 3.9; 39.4…

Primary: Clinical Cure (Defined as a Complete Resolution of Signs and Symptoms) After 14 Days of Treatment at the Test of Cure Visit (Day 17-Day 22) Using Murray Scoring Scale…

Primary: All-Cause Mortality (US FDA Only) — 19; 17; 3; 3 Participants

Primary: Safety and Tolerability, Assessed by Adverse Events, Clinical Laboratory Results, Physical Examination Findings, ECG Results, and Vital Sign Measurements — 1; 1; 0; 0…

Primary: Number of Participants With Global Response of Success or Failure (Based on Clinical and Microbiological Response) at End of Treatment (EOT) — 170; 33 participants

Primary: Percentage of Participants With Treatment Success at End of Study Treatment (EOST) as Determined by Data Review Committee (DRC) — 88.9 Percentage of participants

Primary: Number of Participants With Clinical Efficacy — 76; 73 participants

Primary: Serum Cidal Activity as Tested Against Various Candida Isolates and Reported as Ex-vivo Effect (Log Inhibition of Growth) — 3; 0.5; 0; 3 Log inhibition

Primary: Therapeutic Efficacy 1 — 102; 98 participants — p=0.925

Primary: Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-treat (ITT) Population — 5.1; 42.2…

Primary: Number of Participants With One or More Drug-related Serious Adverse Events — 0 Participants

Primary: Incidence of Treatment Emergent Adverse Events [Safety and Tolerability] — 71; 49; 55 Participants

Primary: Treatment Success at End of Study Treatment (EOST) as Determined by the Data Review Committee (DRC) — 16 Participants

Primary: Percentage of Participants With Global Success at End of Treatment as Determined by the Data Monitoring Committee — 21 Participants

Primary: Percentage of Participants With Non-Candida Invasive Fungal Infections at a Single Institution — 32.3 Percentage of participants